◼ Archived
Health
A precision T-cell therapy stalls treatment-resistant cancers in clinical trial
Marengo Therapeutics' Invikafusp alfa shows promise in treating TMB-H solid tumors resistant to standard immune checkpoint blockade.
1 trends tracked about this subject — the full history, oldest to newest below.
Marengo Therapeutics' Invikafusp alfa shows promise in treating TMB-H solid tumors resistant to standard immune checkpoint blockade.